Literature DB >> 6423794

Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy.

A L de Gee, P P McCann, J M Mansfield.   

Abstract

The drug DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase, was studied as an antitrypanosomal drug. We showed that an antibody response to the surface antigen of trypanosomes was necessary for rapid elimination of parasites after DFMO treatment, as effects of drug treatment were greatly reduced in immunosuppressed mice. Efficacy of the treatment also varied with the inherent ability of different mouse strains to mount antibody responses to trypanosomal surface antigen. Further, some trypanosomes were more resistant to the combined effects of drug and host immunity, as relapses occurred with certain parasite clones.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6423794

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  7 in total

Review 1.  Recent advances in the biochemistry of polyamines in eukaryotes.

Authors:  A E Pegg
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

2.  Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense.

Authors:  C J Bacchi; H C Nathan; T Livingston; G Valladares; M Saric; P D Sayer; A R Njogu; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Effects of alpha-difluoromethylornithine on protein synthesis and synthesis of the variant-specific glycoprotein (VSG) in Trypanosoma brucei brucei.

Authors:  A J Bitonti; D E Cross-Doersen; P P McCann
Journal:  Biochem J       Date:  1988-02-15       Impact factor: 3.857

4.  Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei.

Authors:  S Magez; M Geuskens; A Beschin; H del Favero; H Verschueren; R Lucas; E Pays; P de Baetselier
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

5.  The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice.

Authors:  Stefan Magez; Anita Schwegmann; Robert Atkinson; Filip Claes; Michael Drennan; Patrick De Baetselier; Frank Brombacher
Journal:  PLoS Pathog       Date:  2008-08-08       Impact factor: 6.823

Review 6.  Immune Evasion Strategies of Trypanosoma brucei within the Mammalian Host: Progression to Pathogenicity.

Authors:  Benoît Stijlemans; Guy Caljon; Jan Van Den Abbeele; Jo A Van Ginderachter; Stefan Magez; Carl De Trez
Journal:  Front Immunol       Date:  2016-06-24       Impact factor: 7.561

7.  A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.

Authors:  Freddie Kansiime; Seraphine Adibaku; Charles Wamboga; Franklin Idi; Charles Drago Kato; Lawrence Yamuah; Michel Vaillant; Deborah Kioy; Piero Olliaro; Enock Matovu
Journal:  Parasit Vectors       Date:  2018-02-22       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.